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MI/CrAbstract Purpose: Our aim was to determine the diagnostic accuracy of MI/Cr ratio in determin-
ing the grade of glioma.
Materials and methods: Twenty-two patients (14 males and 8 females), ranging in age from 15–
63 years (mean 34.4 years) were prospectively recruited for this study. All had a brain tumor recently
diagnosed by MRI and had received no previous treatment, except for steroids. They were referred
for MRS examination before surgical biopsy and/or resection or radiotherapy. Ratios for MI/Cr,
Cho/Cr, and Cho/NAA were obtained for each lesion and compared with the grade of the lesion.
Results: The levels of MI/Cr were higher (2.14 ± 1.4) in patients with low-grade astrocytoma, and
lower in patients with anaplastic astrocytoma (0.39 ± 0.11) and GBM (0.025 ± 0.06). 21 out of the
22 patients were correctly classiﬁed using MI/Cr ratio, one patient was misdiagnosed as high grade
glioma and the biopsy revealed grade II glioma. The diagnostic accuracy, sensitivity and speciﬁcity of
MI/Cr ratio for the grading of glioma was 95.4%, 100%, and 92.8%, respectively.
Conclusion: MRShas proven to be an important complementary tool saving the patient from unnec-
essary biopsy taking when it is conclusive thus altering the treatment planning. This study had dem-
onstrated that MI level and MI/Cr ratio are important in presurgical grading of brain tumors.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Cerebral glioma is the most common type of primary brain
tumor, and the prognosis for this disease remains very poor.
Therefore, appropriate therapeutic measures are crucial for
improving the prognosis of this devastating disease. In
determining a treatment plan, tumor grade is a key consideration
for minimizing the risk of unnecessary morbidity andmortality (1).
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tion system dated 2007, brain glial tumors can be classiﬁed into
low grade (grade I and II, benign) and high grade (grade III
and IV) (2).
The current ‘‘gold standard’’ for the determination of gli-
oma grade is by surgical biopsy/resection and histopathologic
assessment. However, biopsy approach may suffer from sev-
eral sources of errors (3,4), the most signiﬁcant of which is lim-
ited number of samples thus creating potential errors in
determining glioma grade. As a result, a high-grade tumor
may be diagnosed as low grade because the samples were taken
at a less malignant region. Alternatively, noninvasive or mini-
mally invasive imaging technologies have been used to evaluate
the malignancy of brain tumors (1).
Because glial tumors have some speciﬁc metabolic charac-
teristics which further differ according to the grade, there is
growing interest in MR spectroscopy that could further in-
crease the sensitivity of routinely used diagnostic imaging (5).
Recent reports regarding MR spectroscopy support its use
as a powerful tool in tumor grading. Speciﬁcally, elevation in
choline (Cho) with depression of N-acetylaspartate (NAA) is
a reliable indicator of tumor (6).
Myo-inositol (MI) is one of the most abundant metabolites
visible on 1H-MRS at short TE (30 ms). It can be detected as a
multiplet of peaks with main components located at 3.5 ppm
of the spectrum (5).
The concentration of MI is signiﬁcantly increased in vari-
ous cerebral diseases (7,8), including brain tumor (9). MI is in-
volved in the activation of protein C kinase. Protein C kinase
leads to the production of protylotic enzymes, which are found
more often in malignant and aggressive primary tumors. Thus
the level of MI as seen by MRS may be helpful for predicting
the histologic grade of brain tumors (9).
The aim of this study was to determine the diagnostic value
of MI/Cr ratio in determining the grade of cerebral glioma
with reference to operative and histopathological results when-
ever possible.
2. Patients and methods
2.1. Patients
During a period from September 2011 to January 2013, 22 pa-
tients (14 males and 8 females), ranging in age from 15–
63 years (mean 34.4 years) were prospectively recruited for this
study. All had a brain tumor recently diagnosed by MRI and
had received no previous treatment, except for steroids. They
were referred for MRS examination before surgical biopsy
and/or resection or radiotherapy.
This study was performed after the approval of the scien-
tiﬁc and ethics committee of the hospital.
2.2. Methods
The study was performed on 1.5-T MR scanner (Gyroscan
Entera, Philips medical systems) using standard imaging head
coil. Images were acquired with the patient on supine position
with a placed head support pillow to minimize the patient’s
movement. The procedure was explained carefully to the pa-
tients. They were asked to relax and stay still during the
examination.Initially, each patient was subjected to routine spin echo
(SE) sequences. The volume of interest (VOI) from the lesion
was selected on SE-T2-weighted images for single voxel
(SVS). The voxel was centered on the region previously noted
to correspond to maximum contrast enhancement. If contrast
enhancement was subtle or not present, the area of maximal
T2 abnormality and mass effect was sampled.
The size of the voxel ranged from 1 · 1 · 1 cm to
2 · 2 · 2 cm according to the size of the lesion. The former
used size of the voxel lead to a more lengthy examination com-
pared to the latter one. So, the time of the whole MRS exam-
ination using the single voxel technique ranged from 40 to
50 min.
The three TE sequences (long, short and intermediate TEs)
were done. SVS studies were performed with Point Resolved
Spectroscopy (PRESS) sequence. Multi-voxel study was per-
formed for one patient.
MRS technique: First: Axial, sagittal and coronal planes of
the brain were done in T2WI:TE = 100, TR = 3658, Field of
view (FOV) 18 · 24 cm and Matrix 192 · 256.
Then, MRS in long TE = 288, short TE = 31 and interme-
diate TE = 144 with TR = 2000 and spectral bw = 1000.
3. Interpretation
Visually the important metabolites to be commented upon are;
- In the long TE were: the Cho (at 3.2 ppm), NAA (at
2.0 ppm), Cr (3.02 ppm) and sometimes the MI (at
3.56 ppm) as well as lipid/lactate peaks (between 1 and
1.5 ppm), however, it is better to comment on them in the
short one.
- Other metabolites seen in the short TE, are MI and lipid/
lactate (between 1 and 1.5 ppm).
- The intermediate TE was done to detect if there is inversion
of the lipid/lactate peak or not, where if seen inverted
denotes lactate. Presence of lipids denotes necrosis while
lactate denotes high grade neoplasm (in neoplastic lesions)
- Important ratios
The intensity and integral values were obtained on each
metabolite, and then we used the intensity value for obtaining
the important ratios which were essential for reaching the diag-
nosis. Ratios for MI/Cr, Cho/Cr, and Cho/NAA were ob-
tained for each lesion and compared with the histologic
grade of the lesion.
The accuracy, sensitivity, and speciﬁcity were calculated for
the correct identiﬁcation of high grade gliomas. Hence, glio-
mas classiﬁed as high grade and found at histological examina-
tion to be of high grade were considered true-positive ﬁndings;
low grade gliomas that were histologically conﬁrmed as low
grade were considered true negative.
4. Results
The tumor grades determined using MRS were compared with
those obtained at histopathology/follow up by conventional
MRI after radiotherapy. Sixteen cases were conﬁrmed histo-
logically via either surgical biopsy and/or resections, with 6
cases treated by radiotherapy. Follow up by conventional
MRI was done in all cases.
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with tumors were classiﬁed as low-grade gliomas, including
WHO grade II (astrocystome (n= 13), oligodendroglioma
(n= 1)), whereas in 8 patients the tumors were classiﬁed asFig. 1 Twenty-three year old patient with a high grade glioma (Glio
that was predominantly cystic. A single voxel (1 · 1 · 1 cm) was placed
mildly elevated Cho, decreased NAA, with estimated Cho/NAA:170,
showing no MI, very high levels of Lipid/lactate peak denoting tumorhigh-grade gliomas, including 2 with WHO grade III (anaplas-
tic astrocytoma) and 6 with WHO grade IV (glioblastomas).
The levels of MI/Cr were higher (2 ± 1.5) in patients with
low-grade astrocytoma, and lower in patients with anaplasticblastoma multiformis) involving the right temporo-parietal region
on a solid component. (a) MRS obtained at long TE (288) showing
Cho/Cr:17 and NAA/Cr:0.1. (b) MRS obtained at short TE (31)
necrosis.
214 L.I.A. Metwally et al.astrocytoma (0.39 ± 0.15) and GBM (0.025 ± 0.06) (Figs. 1–
3) (Table 1).Fig. 2 Sixty-three year old patient with a right temporo-parietal i
perilesional edema. A single voxel (1 · 1 · 1 cm) was placed on the so
Cho, depressed NAA, with estimated Cho/NAA:1.8, Cho/Cr:5.5 a
moderately elevated MI, the MI/Cr:0.39. The lipid/lactate peak is elevOf the 22 patients with veriﬁed gliomas, 21 were correctly
classiﬁed, with one false-positive case who was misdiagnosedntermediate grade glioma (Astrocytoma grade II) with extensive
lid portion. (a) MRS obtained at long TE (288) showing elevated
nd NAA/Cr:2.9. (b). MRS obtained at short TE (31) showing
ated.
Fig. 3 Fifty-three year old patient with a left temporo-parietal para-sylvian low grade glioma (Astrocytoma grade II) with minimal
surrounding edema. A single voxel (1 · 1 · 1 cm) was placed within the lesion. (a) MRS obtained at long TE (288) showing elevated Cho,
depressed NAA, with estimated Cho/NAA:20, Cho/Cr:7.8 and NAA/Cr:0.38. (b). MRS obtained at short TE (31) showing a high level of
MI, with estimated MI/Cr:0.97, together with raised Lipid/lactate peaks.
Table 1 Results of MI/Cr ratios derived from magnetic resonance spectroscopy (MRS) with low-grade, intermediate-grade and High-
grade gliomas.
Low grade astrocytoma Anaplastic astrocytoma GBM
MI/Cr 2 ± 1.5 0.39 ± 0.15 0.025 ± 0.06
Cho/NAA 9.8 ± 7.8 10.9 ± 8.3 33.34 ± 66
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vealed grade II glioma.
The diagnostic accuracy, sensitivity and speciﬁcity of MI/
Cr ratio for the grading of glioma was 95.4%, 100%, 92.8%,
respectively.
5. Discussion
Non-invasive grading of gliomas is still considered a challenge
despite its important role in the prognosis and management of
patients with brain neoplasms (10).
Preoperative grading of gliomas based on conventional MR
imaging is often unreliable (11). The radiologic grading of gli-
omas by conventional MR imaging has a sensitivity ranging
from 55% to 83% (5,6). Low and high grade gliomas may
be differentiated on conventional MR imaging by characteris-
tic differences in the degree of contrast enhancement and the
extent of mass effect and cyst formation, which are more pro-
nounced in higher lesion grades (12). However many high-
grade tumors do not show contrast enhancement in the post-
contrast images, which may yield a false-negative diagnosis
(13,14). This outcome has led to the investigation of advanced
MR imaging for grading (11).
The clinical utility of proton MRS in glioma grading is still
being investigated. At this point, it is important to understand
that MRS is very sensitive to abnormal metabolic changes, but
the speciﬁcity is relatively low (15). The sensitivity, speciﬁcity,
and accuracy of MRS in differentiating between high and low
grade neoplasms are 100%, 86%, and 96%, respectively (16).
The results of glioma grading by using MRS vary widely.
These wide variations may be attributed to different methods
and metabolites overlapping between different tumor grades
(17).
Previous studies have shown the potential of MRS to differ-
entiate low grade from high grade gliomas (6). They used Cho/
Cr, Cho/NAA ratios in the determination of the glioma grade.
They had observed higher Cho/Cr and Cho/NAA in high
grade compared to low grade tumors, though threshold values
of metabolite ratios for grading of gliomas are not well
established.
In this series we did not rely on Cho/Cr or Cho/NAA ratio
for the grading of glioma, in general we found a high level of
Cho in high grade tumors, However high levels for Cho with
high Cho/Cr and high Cho/NAA ratios had been observed
in some low grade gliomas. This was in concordance with
the previous report by law et al. (6) who reported high Cho le-
vel in low grade glioma. On the other hand Hall et al. 2001 re-
ported low Cho level ratios in some GBM (18). This may be
due to extensive necrosis, which increases the false-positive
rates and false-negative rates in predicting low and high grade
gliomas, respectively (19).
In this study we used Cho/NAA, Cho/Cr ratios to differen-
tiate brain tumors from nonneoplastic disorders. We con-
ﬁrmed the diagnosis of glioma versus cortical dysplasia and
encephalitis in four cases based on elevated Cho/NAA, Cho/
Cr together with MI/Cr ratio.
Using short echo MRS (TE 30), MI can also be used to dif-
ferentiate low and high-grade gliomas (20,21). Low-grade gliomas
express higher levels of MI compared with high-grade gliomas.
This may be due to the lack of activation of phosphatidylinositol
metabolism resulting in the accumulation of MI (19).Only few publications have evaluated the diagnostic poten-
tial of MI/Cr ratio in glioma grading. In this study the tumoral
grading was done based on the MI/Cr ratio, we used the results
of Castillo et al., as base line for grading. They demonstrated a
threshold value of 0.82 ± 0.25, 0.33 ± 0.16, and 0.15 ± 0.12
for MI/Cr ratio in predicting low, anaplastic and high grade
tumors, respectively (9).
We were able to differentiate between low grade (II) and
high grade (III + IV) gliomas using the MI/Cr ratio. The lev-
els of MI/Cr were higher (2 ± 1.5) in patients with low-grade
astrocytoma, and lower in patients with anaplastic astrocy-
toma (0.39 ± 0.11) and GBM (0.025 ± 0.06).
This was an agreement with Majos and his colleague who
reported that MI at short TE provided some separation be-
tween low grade astrocytoma and anaplastic astrocytoma. In
addition it showed a signiﬁcant difference between tumor
groups which are difﬁcult to differentiate (low grade astrocy-
toma versus GMB-metastases, and anaplastic astrcytoma ver-
sus GMB-metastases) (22).
Aydin et al. tried to make another variation by using Cho/
MI for the categorization of tumors according to their malig-
nancy rate and differentiation from non neoplastic lesions.
They demonstrated that the Cho/MI ratio is a good diagnostic
tool in glioma grading, with the highest Cho/MI ratio found in
GBM and lowest Cho/MI ratio found in low grade gliomas
(23).
However our results disagreed with the previous reports by
Kousi and his colleagues who used 3T 1H-MRS in grading
cerebral gliomas at short and long TE in 71 patients with un-
treated glioma (24). MI was observed to be increased for both
glioma grades, the MI/Cr ratio was 0.85 ± 0.24 and
0.90 ± 0.35 for low and high grade gliomas, respectively and
hence that ratio did not signiﬁcantly differentiate the two tu-
mor groups.
Kim et al. (25) also used 3T MR-spectroscopy for the grad-
ing of glioma in 35 patients. They found that MI/Cr ratio in-
creased with grade of the tumor with the MI/Cr ratio being
0.86 ± 0.19, 1.23 ± 0.37, 1.15 ± 0.52 for grade II, grade III,
and grade IV tumors, respectively (25).
In this study the accuracy of MI/Cr for predicting the gli-
oma grade was high. One case was diagnosed as anaplastic gli-
oma based on the MI/Cr ratio however the biopsy revealed
grade II glioma, this may be explained that the biopsy was
not necessarily taken within the area of the lesion with greatest
cellularity, so it may underestimate the tumor grade (26,27).
In our series one case was diagnosed as low grade astrocy-
toma, however a follow up MRI done after 1 year showed pro-
gressive increase in the size of the lesion, with a newly
developed large cystic component, and the pathology revealed
mixed astrocytoma grades II and III. This may be attributed
either to the increase of the tumor grade over this considerable
period of time or depends on the voxel site that was not at the
same location of the biopsy site.
Previous studies by Castillo et al. and Smith et al. found
that oligodendroglioma and mixed oligoastrocytoma have
spectroscopic characteristics similar to high-grade astrocy-
toma, with high levels of choline, but may also have elevated
MI (9,28). In our study we have one case of oligodendrogli-
oma, which showed in addition to the elevated Cho level,
mildly elevated lipid/lactate peaks, the MI was elevated as well
with the MI/Cr ratio being 0.65.
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grade gliomas and have also been shown to be useful in differ-
entiating low and high-grade gliomas (29). In this study high
lipid/lactate peak was observed in 6 cases of high grade
GBM cases.
The limitations of the study included small sample size
which may reduce or bias the power of the results. Also not
all low grade glioma underwent biopsy however they followed
up after treatment with radiotherapy. Lastly, because only a
single-voxel technique was used, the possibility of sampling er-
rors in tumors of heterogeneous appearance cannot be
excluded.
6. Conclusion
MRS has proven to be an important complementary tool sav-
ing the patient from unnecessary biopsy taking when it is con-
clusive thus altering the treatment planning. This study had
demonstrated that the MI level and the MI/Cr ratio are impor-
tant in presurgical grading of brain tumors.
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